Background: There is a preclinical rationale for inhibiting angiogenesis in mesothelioma. We aimed to assess the efficacy and safety of the anti-VEGFR-2 antibody ramucirumab combined with gemcitabine in patients with pretreated malignant pleural mesothelioma [ as a second-line treatment … More
Main Navigation Menu
➤ Find Out Who Was Exposed to Asbestos and How
➤ North Carolina Asbestos Exposure Work / Job Sites
➤ Asbestos-Contaminated Talc Mesothelioma Lawsuits
➤ Mesothelioma / Lung Cancer / Asbestosis: Basic Facts
➤ How to Get Legal Compensation for Your Case
➤ Case Evaluation — Free. Confidential. No Obligation.
➤ Questions New Clients Have Asked Us (FAQs)
➤ Information About Our Law Firm
➤ Asbestos Attorney Tom Lamb
➤ Collection of News and Reports
You can use our Quick Contact Form to tell us about your case.
Recent News & Reports
Adding Atezolizumab to Neoadjuvant Cisplatin-Pemetrexed a Feasible Option in Malignant Pleural Mesothelioma
A three-agent neoadjuvant regimen that combines a PD-L1 inhibitor with chemotherapy appears feasible for patients with malignant pleural mesothelioma, according to an ongoing phase I trial. The findings [ about neoadjuvant therapy ] were presented at the International Association for the Study of … More
Nivo/Ipi Combo Now ‘Standard of Care’ in Mesothelioma
The [ combination immunotherapy consisting ] of nivolumab (Opdivo) and ipilimumab (Yervoy) offers a durable, long-term survival benefit over chemotherapy for patients with unresectable malignant pleural mesothelioma (MPM), confirms a 3-year updated analysis of the CheckMate 743 trial. After 3 … More
Access to care varies greatly among patients with malignant pleural mesothelioma
Access to care varied significantly among patients with stage I to stage III malignant pleural mesothelioma, according to study results. The findings — presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer — showed variations in access based on … More
More Data in Support of Surgery for Malignant Pleural Mesothelioma
Patients with malignant pleural mesothelioma (MPM) lived 6 months longer, on average, when they had surgery in addition to chemotherapy, a large retrospective analysis showed. The addition of surgery to combination chemotherapy resulted in a median overall survival (OS) of 22 months as compared … More
Appeals court reinstates suit by Solano County woman against Johnson & Johnson over baby powder
A state appeals court reinstated a lawsuit Tuesday by the widow of a Solano County man who died of cancer after using Johnson & Johnson talcum powder for most of his life. A judge had dismissed the suit by Douglas Strobel and his wife, Jo Ann Strobel, saying their medical witnesses had no … More